



(51) International Patent Classification:

A61K 31/444 (2006.01) *A61P 5/00* (2006.01)
A61P 1/16 (2006.01) *G01N 33/53* (2006.01)
A61P 35/00 (2006.01) *G01N 33/86* (2006.01)

(21) International Application Number:

PCT/US2024/021308

(22) International Filing Date:

25 March 2024 (25.03.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/455,193 28 March 2023 (28.03.2023) US

(71) Applicant: **CRINETICS PHARMACEUTICALS, INC.**

[US/US]; 6055 Lusk Blvd., San Diego, California 92121 (US).

(72) Inventors: **GOULET, Lance**; c/o Crinetics Pharmaceuti-

cals, Inc., 6055 Lusk Blvd., San Diego, California 92121 (US). **HUMPHREYS, William**; c/o Crinetics Pharmaceuti-
cals, Inc., 6055 Lusk Blvd., San Diego, California 92121 (US). **MADAN, Ajay**; c/o Crinetics Pharmaceuticals, Inc.,
6055 Lusk Blvd., San Diego, California 92121 (US). **LUO, Sha**; c/o Crinetics Pharmaceuticals, Inc., 6055 Lusk Blvd.,
San Diego, California 92121 (US).

(74) Agent: **CAPPS, Kevin** et al.; c/o Crinetics Pharmaceuti-
cals, Inc., Legal IP, 6055 Lusk Blvd., San Diego, California
92121 (US).

(81) Designated States (*unless otherwise indicated, for every*

kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every*

kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: COMPOSITIONS AND METHODS FOR ADMINISTERING PALTUSOTINE TO PATIENTS WITH HEPATIC IM-
PAIRMENT




FIG. 5

(57) Abstract: Provided are compositions and methods for administering paltusotine, or a pharmaceutically acceptable salt thereof, to a patient having hepatic impairment.

[Continued on next page]

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*